Published in Cell Cycle on June 16, 2017
Patient-Derived Orthotopic Xenograft (PDOX) Models of Melanoma. Int J Mol Sci (2017) 0.75
Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med (2011) 45.46
Phase I study of the intravenous administration of attenuated Salmonella typhimurium to patients with metastatic melanoma. J Clin Oncol (2002) 4.15
Tumor-targeted Salmonella as a novel anticancer vector. Cancer Res (1997) 3.45
Tumor-targeting bacterial therapy with amino acid auxotrophs of GFP-expressing Salmonella typhimurium. Proc Natl Acad Sci U S A (2005) 2.76
Engineering the perfect (bacterial) cancer therapy. Nat Rev Cancer (2010) 2.70
Biodistribution and genetic stability of the novel antitumor agent VNP20009, a genetically modified strain of Salmonella typhimurium. J Infect Dis (2000) 2.63
Targeted therapy with a Salmonella typhimurium leucine-arginine auxotroph cures orthotopic human breast tumors in nude mice. Cancer Res (2006) 2.51
Monotherapy with a tumor-targeting mutant of Salmonella typhimurium cures orthotopic metastatic mouse models of human prostate cancer. Proc Natl Acad Sci U S A (2007) 2.46
Exploring long-term protection of normal human fibroblasts and epithelial cells from chemotherapy in cell culture. Oncotarget (2011) 2.28
Target for cancer therapy: proliferating cells or stem cells. Leukemia (2006) 2.15
Efficacy of a genetically-modified Salmonella typhimurium in an orthotopic human pancreatic cancer in nude mice. Anticancer Res (2009) 1.81
Monotherapy with a tumor-targeting mutant of S. typhimurium inhibits liver metastasis in a mouse model of pancreatic cancer. J Surg Res (2009) 1.76
Matching targets for selective cancer therapy. Drug Discov Today (2003) 1.75
The bulge area is the origin of nestin-expressing pluripotent stem cells of the hair follicle. J Cell Biochem (2011) 1.74
Teratogens as anti-cancer drugs. Cell Cycle (2005) 1.70
Tissue-selective therapy of cancer. Br J Cancer (2003) 1.59
Treatment with inhibitors of caspases, that are substrates of drug transporters, selectively permits chemotherapy-induced apoptosis in multidrug-resistant cells but protects normal cells. Leukemia (2001) 1.58
Melanoma resistance: a bright future for academicians and a challenge for patient advocates. Mayo Clin Proc (2014) 1.57
Efficacy of Salmonella typhimurium A1-R versus chemotherapy on a pancreatic cancer patient-derived orthotopic xenograft (PDOX). J Cell Biochem (2014) 1.55
Vessel destruction by tumor-targeting Salmonella typhimurium A1-R is enhanced by high tumor vascularity. Cell Cycle (2010) 1.41
Comparison of efficacy of Salmonella typhimurium A1-R and chemotherapy on stem-like and non-stem human pancreatic cancer cells. Cell Cycle (2013) 1.41
Tumor-targeting Salmonella typhimurium A1-R decoys quiescent cancer cells to cycle as visualized by FUCCI imaging and become sensitive to chemotherapy. Cell Cycle (2014) 1.30
Efficacy of tumor-targeting Salmonella typhimurium A1-R in combination with anti-angiogenesis therapy on a pancreatic cancer patient-derived orthotopic xenograft (PDOX) and cell line mouse models. Oncotarget (2014) 1.25
Efficacy of tumor-targeting Salmonella typhimurium A1-R on nude mouse models of metastatic and disseminated human ovarian cancer. J Cell Biochem (2014) 1.13
Tumor-targeting Salmonella typhimurium A1-R arrests growth of breast-cancer brain metastasis. Oncotarget (2015) 1.12
Cancer-cell killing by engineered Salmonella imaged by multiphoton tomography in live mice. Anticancer Res (2012) 1.11
Determination of the optimal route of administration of Salmonella typhimurium A1-R to target breast cancer in nude mice. Anticancer Res (2012) 1.10
Tumor-targeting Salmonella typhimurium A1-R in combination with doxorubicin eradicate soft tissue sarcoma in a patient-derived orthotopic xenograft (PDOX) model. Oncotarget (2016) 1.09
Intraperitoneal administration of tumor-targeting Salmonella typhimurium A1-R inhibits disseminated human ovarian cancer and extends survival in nude mice. Oncotarget (2015) 1.05
Facilitating T Cell Infiltration in Tumor Microenvironment Overcomes Resistance to PD-L1 Blockade. Cancer Cell (2016) 1.03
High efficacy of tumor-targeting Salmonella typhimurium A1-R on a doxorubicin- and dactolisib-resistant follicular dendritic-cell sarcoma in a patient-derived orthotopic xenograft PDOX nude mouse model. Oncotarget (2016) 1.03
Antitumor effect of VNP20009, an attenuated Salmonella, in murine tumor models. Oncol Res (2001) 1.01
Tumor-Targeting Salmonella typhimurium A1-R in Combination with Trastuzumab Eradicates HER-2-Positive Cervical Cancer Cells in Patient-Derived Mouse Models. PLoS One (2015) 1.01
Tumor amplified protein expression therapy: Salmonella as a tumor-selective protein delivery vector. Oncol Res (2000) 1.00
Methods for the development of tumor-targeting bacteria. Expert Opin Drug Discov (2014) 0.95
Efficacy of Tumor-Targeting Salmonella A1-R on a Melanoma Patient-Derived Orthotopic Xenograft (PDOX) Nude-Mouse Model. PLoS One (2016) 0.95
Melanin content in melanoma metastases affects the outcome of radiotherapy. Oncotarget (2016) 0.94
Comparison of the selective targeting efficacy of Salmonella typhimurium A1-R and VNP20009 on the Lewis lung carcinoma in nude mice. Oncotarget (2015) 0.93
Vemurafenib-resistant BRAF-V600E-mutated melanoma is regressed by MEK-targeting drug trametinib, but not cobimetinib in a patient-derived orthotopic xenograft (PDOX) mouse model. Oncotarget (2016) 0.89
Antitumour effects of genetically engineered Salmonella in combination with radiation. Eur J Cancer (2000) 0.87
Tumor-targeting Salmonella typhimurium A1-R combined with temozolomide regresses malignant melanoma with a BRAF-V600E mutation in a patient-derived orthotopic xenograft (PDOX) model. Oncotarget (2016) 0.85
Tumor-targeting Salmonella typhimurium A1-R Sensitizes Melanoma with a BRAF-V600E Mutation to Vemurafenib in a Patient-derived Orthotopic Xenograft (PDOX) Nude Mouse Model. J Cell Biochem (2017) 0.81
Tumor-targeting Salmonella typhimurium A1-R regresses an osteosarcoma in a patient-derived xenograft model resistant to a molecular-targeting drug. Oncotarget (2016) 0.79
High-efficacy targeting of colon-cancer liver metastasis with Salmonella typhimurium A1-R via intra-portal-vein injection in orthotopic nude-mouse models. Oncotarget (2016) 0.75
Color-coded intravital imaging demonstrates a transforming growth factor-β (TGF-β) antagonist selectively targets stromal cells in a human pancreatic-cancer orthotopic mouse model. Cell Cycle (2017) 0.76
Patient-derived orthotopic xenograft (PDOX) mouse model of adult rhabdomyosarcoma invades and recurs after resection in contrast to the subcutaneous ectopic model. Cell Cycle (2016) 0.75
Prognostic and predictive biomarkers for the benefit of immunotherapy in patients with metastatic melanoma. Br J Dermatol (2016) 0.75
Intra-arterial administration of tumor-targeting Salmonella typhimurium A1-R regresses a cisplatin-resistant relapsed osteosarcoma in a patient-derived orthotopic xenograft (PDOX) mouse model. Cell Cycle (2017) 0.75
Combination of gemcitabine and docetaxel regress both gastric leiomyosarcoma proliferation and invasion in an imageable patient-derived orthotopic xenograft (iPDOX) model. Cell Cycle (2017) 0.75